The molecular underpinnings of prostate cancer: impacts on management and pathology practice

Daniel Nava Rodrigues(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust)

The Journal of Pathology

October 18, 2016

10.1002/path.4826

Cited by 43

Related Papers

DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

|New England Journal of Medicine|2015|2.2k

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

|New England Journal of Medicine|2020|760

METastasis Reporting and Data System for Prostate Cancer: Practical Guidelines for Acquisition, Interpretation, and Reporting of Whole-body Magnetic Resonance Imaging-based Evaluations of Multiorgan Involvement in Advanced Prostate Cancer

|European Urology|2016|326

Poly(ADP-Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

|CA A Cancer Journal for Clinicians|2011|209

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

|Cancer Discovery|2021|160